The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been demonstrated to reduce the composite of myocardial infarction, stroke, or cardiovascular death in patients with established atherosclerotic cardiovascular disease. To our knowledge, long-term cost-effectiveness of this therapy has not been evaluated using clinical trial efficacy data.
D espite major advances in the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), substantial risk of recurrent cardiac events, stroke events, and cardiovascular death remains as well as high disease burden affecting quality of life and costs. [1] [2] [3] [4] [5] [6] [7] Lowering lowdensity lipoprotein (LDL) cholesterol levels with certain therapies, including statins, reduces cardiovascular events. 8, 9 Yet, many patients with established ASCVD need further LDL cholesterol lowering and remain at substantial risk for cardiovascular events despite optimal statin therapy. 1, 4, 9 In the past 5 14 demonstrated that the addition of evolocumab to standard background therapy, including moderate-to highintensity statin therapy, reduced incidence of cardiovascular events in patients with established ASCVD. Cost-effectiveness of new therapies is important as health care costs rise, and accurate information about value and potential tradeoffs among therapies is essential. Several analyses have assessed the potential economic value of PCSK9 inhibitors in patient populations with varied risk levels, 7, [15] [16] [17] [18] extrapolating cardiovascular event reduction rate ratios per 38.67 mg/dL of LDL cholesterol reduction observed in the Cholesterol Treatment Trialists Collaboration (CTTC) metaanalyses of statin trials (to convert LDL cholesterol to millimoles per liter, multiply by 0.0259). 8, 19, 20 To our knowledge, the FOURIER results provide the first opportunity to assess cost-effectiveness of evolocumab for the reduction of subsequent cardiovascular events in an ASCVD population using specific PCSK9 inhibition trial-based efficacy data. In this study, a Markov cohort state-transition model was used to assess the cost-effectiveness of evolocumab when added to standard background therapy in clinical practice patients with established ASCVD from a societal and US health plan perspective to help better identify the patient populations and value-based price where the use of evolocumab treatment would provide value.
Methods

Model Structure
A Markov cohort state-transition model was used, considering the US societal perspective and assuming lifetime horizon to capture the lifetime progression of ASCVD in adults. A similar model to that used previously to estimate costeffectiveness and value-based price range of evolocumab using LDL cholesterol-lowering data from the statin trials and cardiovascular event reduction from CTTC meta-analyses 7,17 was used. The model (eFigure 1 in the Supplement) was used to predict subsequent cardiovascular events and cardiovascular-or noncardiovascular-related mortality as a function of age, sex, LDL cholesterol level, and cardiovascular event history. The model transition-states were adapted to match those analyzed in FOURIER. 14 The model comprises mutually exclusive health states that include ASCVD, 2 acute event states (myocardial infarction and ischemic stroke for a 1-year duration), and postevent health states and their combination that are introduced to enable the model to account for event recurrence. In addition, distinctions are made between cardiovascular and noncardiovascular death. Revascularization is included as a procedure and not as a separate health state because it is assumed that it does not affect cardiovascular event risk or quality of life.
Patient Population
A representative clinical practice-based population with established ASCVD was modeled to embody the US patient population. Patients were selected from the US populationweighted National Health and Nutrition Examination Surveys based on individuals 18 years or older (mean age, 66 years) with a recorded atherosclerotic cardiovascular condition and LDL cholesterol level of at least 70 mg/dL (mean, 104 mg/dL) while receiving statin therapy ( Table 1) . Written informed consent was obtained from National Health and Nutrition Examination Survey participants. The survey was approved by the National Center for Health Statistics ethics review board. The Truven MarketScan database, a large-scale database of claims for commercially insured patients and patients with Medicare Supplemental insurance, was used to estimate contemporary cardiovascular event rates for US patients with ASCVD. 15 However, cardiovascular-related death data were not complete in MarketScan. Cardiovascular mortality rates were estimated by combining multiple National Health and Nutrition Examination Surveys death files (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) and National Vital Statistics Report 2012. 15 Rates were adjusted by baseline LDL cholesterol levels and age and previous event history. 21 Ten-year and lifetime event rates for this population are shown in eTable 1 in the Supplement. These rates reflect multiple events. For reference, the annual cardiovascular event rate (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) was 6.4 per 100 patient-years in this
Key Points
Question What is the cost-effectiveness of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab in patients with atherosclerotic cardiovascular disease?
Findings In this study, a Markov cohort state-transition model determined that adding evolocumab at current list price to patients receiving standard background therapy was estimated to cost $268 637 per quality-adjusted life-year gained. Sensitivity and scenario analyses demonstrated incremental cost-effectiveness ratios ranging from $100 193 to $488 642 per quality-adjusted life-year.
Meaning To achieve a threshold of $150 000 per quality-adjusted life-year gained in patients with atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 70 mg/dL and an annual event rate of 6.4 per 100 patient-years, an annual net price of $9669 or a higher risk population would need to be treated.
US practice-based population, whereas in participants in the FOURIER trial placebo plus standard background therapy arm, the event rate (including multiple events) was 4.2 per 100 patient-years (eTable 2 in the Supplement). 14 The noncardiovascular mortality rate was assumed to be that of the general US population.
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Intervention Effects and Model Assumptions
Hazard ratios were based on landmark analysis of the individual end points in FOURIER of nonfatal myocardial infarction, nonfatal ischemic stroke, and coronary revascularization, with respective risk reductions of 21%, 26%, and 16% in the first year and 36%, 25%, and 28% beyond year 1 ( Table 2) , as previously published. 14 Cardiovascular event rate ratios per 38.67 mg/dL of LDL cholesterol reduction were derived from the hazard ratios and the LDL cholesterol reduction reported in the trial (53.36 mg/dL) and then applied in the model (Table 2 ). In FOURIER, cardiovascular mortality reduction was not observed within the first 3 years of follow-up. In the base case, risk reduction for cardiovascular mortality was set at 0% for the first 5 years and then estimated to proportionally match the cardiovascular mortality event reduction in the CTTC meta-analysis 8 for overall or more vs less intensive statin therapy when appropriate thereafter (risk reduction 9.5% per 38.67 mg/dL LDL cholesterol reduction) (eTable 3 in the Supplement). The 5-year delay before the emergence of cardiovascular mortality reduction was selected in the base case to be consistent with findings from contemporary greater-intensity LDL cholesterol-lowering clinical outcome trials in which cardiovascular mortality reduction was not observed in the first 5 years. 9,27,28 Consistent with the safety profile reported in FOURIER, among patients receiving evolocumab, 2.1% were assumed to develop mild injection site reactions over 2 years, resulting in a small quality-of-life decrement (Table 2) . Evolocumab therapy persistence rates over time were based on those observed in FOURIER during the first 3 years of follow-up and then kept steady. Within-trial persistence and adherence effects on efficacy were already reflected in the intention-to-treat hazard ratios reported in FOURIER during the first 3 years and modeled as not further varying.
Costs and Utilities
Direct medical costs associated with cardiovascular events were obtained through US claims data 23,24 and adjusted for inflation to January 2017 using the Consumer Price Index. 29 Indirect cost estimates were obtained from the 2017 American Heart Association/American Stroke Association report on cardiovascular disease burden by applying reported ratios of direct and indirect costs. 25 Noncardiovascular death events were assumed to incur no costs and not vary by treatment allocation. Medication cost of evolocumab in the base case was based on the current wholesale acquisition cost for evolocumab, $14 523 (list price). Additional analyses were performed based on the estimated mean annual net cost of $10 311 (list price minus an average rebate of 29% for branded pharmaceuticals).
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The average of Red Book prices and the market share of generic simvastatin and atorvastatin were used for standard therapy ($68) and ezetimibe ($2780). 31 Additional analyses used ezetimibe priced similarly to generic statin therapy ($68). Util- 
Sensitivity and Scenario Analyses
Sensitivity analyses were conducted to reflect uncertainty in model inputs and to assess robustness of model outcomes. In the deterministic sensitivity analyses, model parameter values (Table 2) were varied individually through plausible ranges (eg, 95% confidence intervals). Probabilistic sensitivity analyses examined the combined effect of parameter uncertainty on the model results. A sensitivity analysis was performed using the FOURIER patient population characteristics and cardiovascular event rates analyses. We also analyzed in the clinical practice population analyses where the background cardiovascular event rates were 25% and 50% higher or lower of those in US clinical practice. As a sensitivity analysis, a range of cardiovascular mortality effect sizes were applied to assess the effect on overall results (eTable 3 in the Supplement). Additional sensitivity analyses included extreme cases where all hazard ratios were increased or decreased simultaneously by 1 SE. A range of scenario analyses were considered including modeling a 3-year, 7-year, or infinite delay of treatment effect on cardiovascular mortality; modeling treatment effect on myocardial infarction, stroke, and cardiovascular mortality based on the corresponding key secondary end point from FOURIER; and modeling cost-effectiveness confined to patients with ASCVD with baseline LDL cholesterol levels of at least 100 mg/dL (mean, 130 mg/dL). A scenario analysis was performed where the risk ratios derived from the FOURIER key secondary end point did not vary from year 1 and subsequent years. In addition, scenario analyses with ezetimibe priced similarly to generic statin therapy ($68), where all patients with ASCVD were treated with ezetimibe and statin therapy and where only the US payer perspective was considered (no indirect costs) were performed. We also analyzed what LDL cholesterol treatment initiation threshold for the population would yield an ICER of $150 000 per QALY gained at current list price and current net drug price (valuebased LDL-cholesterol treatment initiation threshold). Furthermore, we determined the annual event rate thresholds where the current list price and net price of evolocumab would yield an ICER of $150 000.
The 
Results
In the base case using a US clinical practice patient population, the LDL cholesterol level was at least 70 mg/dL (mean, 104 mg/dL) and the cardiovascular event rate was 6.4 per 100 patient-years with standard background therapy. In this base case, mean lifetime costs would be $234 877 per patient treated with standard therapy and $340 275 per patient treated with evolocumab added to standard background therapy, with incremental costs of $105 398 ( Table 3 ;eTable6intheSupple-ment). The lifetime QALY was 7.23 with standard background therapy and 7.62 with evolocumab, with a difference in health effects of 0.39 QALY. Compared with standard background therapy alone, use of evolocumab at its current list price ($14 523) results in an ICER of $268 637 per QALY gained (Table 3) . If, instead, a net price of evolocumab reflecting a 29% discount was used ($10 311), the ICER would be $165 689 per QALY. To achieve a value threshold of $150 000 per QALY gained, a value-based net price of $9669 annually would be required (Table 3 ). The net value-based prices at ICERs of $50 000, $100 000, $150 000, $200 000, and $250 000 per QALY would be $5578, $7623, $9669, $11 715, and $13 760 per year, respectively. For the FOURIER trial participants, the ICER would be $413 579 per QALY, and the net value-based price would be $6780 (Table 3 ). Net value-based prices at ICERs of $50 000, $100 000, $150 000, $200 000, and $250 000 per QALY would be $3843, $5312, $6780, $8249, and $9718 per year, respectively.
Sensitivity Analyses
When we varied the background cardiovascular event rates for the US clinical practice population by 25% and 50% higher or lower, the ICER ranged from $194 551 to $488 642 per QALY, and the net value-based price ranged from $12 218 to $6164 ( Table 4 and Figure) . Testing the treatment benefit for cardiovascular mortality beginning after 5 years of follow-up across risk reductions ranging from 14.0% to 6.4% per 38.67 mg/dL LDL cholesterol yielded an ICER range from $225 575 to $313 163 per QALY and a net value-based price range from $10 773 to $8872 (Table 4 ). Deterministic sensitivity analyses are presented in eFigure 2 in the Supplement. Probabilistic sensitivity analyses at list price revealed a mean ICER of $275 124 per QALY and a mean net value-based price of $9565, with 95% of values between $6313 and $12 418. The probabilistic mean and 95% credible intervals of the net value-based prices are shown in eFigure 3 in the Supplement.
Scenario Analyses
We tested various assumptions of the treatment benefit (Table 4) . A 3-year time before cardiovascular mortality benefits emerge yielded an ICER of $245 066 and a value-based net price of $10 221 per year. A 7-year delay in the cardiovascular mortality treatment benefit yielded an ICER of $293 720 per QALY, and a net value-based price of $9188 per year. In the case of no lifetime cardiovascular mortality reduction, the ICER was $483 800 per QALY, and the net value-based price was $7246. This reflects the improvements in the rate of subsequent events, health state utilities (the quality of the lifeyears), and cardiovascular disease events and procedures costs by reducing nonfatal events, even in the absence of direct survival benefit. Additional scenarios are shown in Table 4 . If all patients were receiving ezetimibe and statin therapy, then the ICER was $271 313. When only the US payer perspective was integrated into the model, then the ICER was $304 392 per QALY, and the net value-based price was $8206. At current list price, the LDL cholesterol treatment initiation threshold for patients with ASCVD that would yield an ICER of $150 000 per QALY was calculated to be at least 119 mg/dL (at this threshold, mean LDL cholesterol level for the ASCVD population is 144 mg/dL) and at the discounted price at least 80 mg/dL (at this threshold, mean LDL cholesterol level for the ASCVD population is 110 mg/dL). The annual event rate for the ASCVD population that would yield an ICER of $150 000 per QALY was calculated to be 13.5 per 100 patient-years at list price and 7.1 per 100 patient-years at the discounted price.
Discussion
In this study, a model based on the clinical risk reduction demonstrated in FOURIER and extrapolated over lifetime was used to investigate the economic value of evolocumab in a US clinical practice-based population of patients with established ASCVD. This evaluation has found that evolocumab at its current list price of $14 523, when added to standard background therapy, including statins, in patients with established ASCVD with a background event rate of 6. 32,33 The treatment effect on cardiovascular mortality in the base case is supported by data from mendelian randomization analyses demonstrating virtually identical lower odds of coronary heart disease mortality in patients with lifelong genetically mediated lower LDL cholesterol levels either from variants in 3-hydroxy-3-methylglutaryl-coenzyme A reductase or in PCSK9. 36 In the scenario that no cardiovascular mortality benefit was to emerge, the ICER would be $483 800 per QALY gained, substantially exceeding current intermediate value and cost-effectiveness thresholds. The base case reflects the characteristics and event rates of patients with ASCVD in US clinical practice. If the characteristics and event rates are a Value-based price is net annual price to achieve an incremental cost-effectiveness ratio of $150 000 per quality-adjusted life-years. Targeting a subset of patients with ASCVD who are at particularly high risk for events based on clinical factors, formal risk scores, or use of a higher LDL cholesterol treatment initiation threshold for the addition of evolocumab therapy would be alternative approaches to improve value and limit expenditures. 16 At an LDL cholesterol treatment initiation threshold of at least 100 mg/dL, evolocumab therapy would be costeffective with an ICER of $100 193 per QALY for a US clinical practice ASCVD population, with an event rate of 6.4 per 100 patient-years, but only at a net price of $10 311. This study provides, to our knowledge, the first costeffectiveness data on evolocumab integrating the results of FOURIER. Prior cost-effectiveness analyses of PCSK9 inhibition have been published based on the projected benefits of LDL cholesterol lowering on clinical events, with variable findings.
15-17 A prior analysis using a similar model from a US payer perspective suggested therapy at list price was costeffective for patients with established ASCVD and LDL cholesterol levels of 100 mg/dL or higher. 17 In contrast, a study a Value-based price is net annual price to achieve an incremental cost-effectiveness ratio of $150 000 per quality-adjusted life-year.
using the Coronary Heart Disease Policy model from a US payer/ health system perspective concluded that PCSK9 inhibition was not cost-effective. 16 Several methodological differences may account for the discrepancies in these prior modeling studies and the Coronary Heart Disease Policy model may underestimate event risk overall. 37, 38 The policy model did not consider indirect costs.
Limitations
This study has several limitations. The results should be interpreted within the context of the data inputs and modeling assumptions used. Clinical outcomes data from FOURIER were limited to a median follow-up of 26 months, yet model predictions are based on the assumption that clinical benefits extend beyond the period with direct follow-up. If the clinical benefits differ from those modeled in this study, particularly in regards to the magnitude and timing of cardiovascular mortality reductions, the cost-effectiveness findings could be affected by overestimating or underestimating the costeffectiveness of evolocumab therapy. Cost-effectiveness estimates could also be altered if significant adverse events materialize beyond 3 to 4 years of observation to date. 39 If the levels of persistence with and adherence to evolocumab therapy differ from those in FOURIER, costs and clinical effectiveness may be affected. This economic evaluation included indirect costs to apply the US societal perspective, as is preferred, 32 but detailed data on indirect costs for each conditional state are limited. This analysis is only applicable to US patients with established ASCVD and is not generalizable to primary prevention patients, other populations at lower cardiovascular event risk, or patients outside the United States.
Conclusions
At its current list price of $14 523, the addition of evolocumab to standard background therapy in patients with ASCVD provides a treatment option that exceeds generally accepted costeffectiveness thresholds. To achieve an ICER of $150 000 per QALY gained in a US clinical practice ASCVD population with an annual event rate of 6.4 per 100 patient-years, a price reduction with a net annual price of $9669 or with an annual net price of $10 311 targeting treatment in patients with LDL cholesterol levels of 80 mg/dL or higher would be needed. For the FOURIER trial participants, with an annual event rate of 4.2 per 100 patient-years, a net annual price of $6780 would be necessary. These findings highlight the need for a comprehensive disease management approach for ASCVD that includes vigorous lifestyle changes, assiduous adherence to all guideline-directed therapies, and judicious use of new, more costly therapies. 
